Endocare Stock Wins a Listing on Nasdaq
Irvine medical device maker Endocare Inc. said Monday its stock has been approved for listing on the Nasdaq National Market.
The company’s common stock, which has been trading on the Nasdaq SmallCap Market, will begin trading today on the national market under the same symbol ENDO.
The medical device company develops, manufactures and markets cryosurgical technologies, which use extremely cold temperatures to freeze and destroy cells. The company initially concentrated on developing devices for the treatment of the two most common diseases of the prostate: prostate cancer and benign prostate hyperplasia.
Endocare is also developing cryosurgical technologies for treating tumors in other organs, including the kidney, breast and liver.
The company, which has 11.3 million shares outstanding, lost $9.3 million last year on revenue of $3.5 million.
The stock closed Monday at $14.06, off 6 cents a share.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
